Circulating tumor cell enumeration in a phase II trial of a four-drug regimen in advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 14, Issue 2, 2015, Pages 115-122.e2

  Krebs, Matthew G ^a,b,c   Renehan, Andrew G ^a,c   Backen, Alison ^a   Gollins, Simon ^d   Chau, Ian ^e   Hasan, Jurjees ^b   Valle, Juan W ^b,c   Morris, Karen ^a   Beech, Janette ^b   Ashcroft, Linda ^b   Saunders, Mark P ^b   Dive, Caroline ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d GLAN CLWYD HOSPITAL   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Biomarker; CellSearch; Cetuximab; Circulating tumor cells; Colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FLUOROURACIL; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; INTESTINE OBSTRUCTION; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; CONTROLLED STUDY; FOLLOW UP; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY; SURVIVAL RATE; TUMOR EMBOLISM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; CETUXIMAB; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84929507812     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2014.12.006     Document Type: Article

References (46)

1. J. Ferlay, E. Steliarova-Foucher, and J. Lortet-Tieulent Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 2013 1374 1403
2. R.M. Goldberg, M.L. Rothenberg, and E. Van Cutsem The continuum of care: a paradigm for the management of metastatic colorectal cancer Oncologist 12 2007 38 50
3. E. Van Cutsem, B. Nordlinger, A. Cervantes ESMO Guidelines Working Group Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment Ann Oncol 21 suppl 5 2010 v93 v97
4. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
5. L.B. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
6. A. Sobrero, S. Ackland, and S. Clarke Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer Oncology 77 2009 113 119
7. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
8. J.Y. Douillard, S. Siena, and J. Cassidy Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
9. J. Tabernero, E. Van Cutsem, and E. Diaz-Rubio Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25 2007 5225 5232
10. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
11. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
12. F. Di Nicolantonio, M. Martini, and F. Molinari Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
13. J.-Y. Douillard, K.S. Oliner, and S. Siena Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
14. A. Grothey, D. Sargent, R.M. Goldberg, and H.-J. Schmoll Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 2004 1209 1214
15. H.Y. Sheikh, J.W. Valle, and T. Waddell Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer Br J Cancer 99 2008 577 583
16. A. Falcone, S. Ricci, and I. Brunetti Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 2007 1670 1676
17. F. Loupakis, C. Cremolini, and G. Masi FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): results of the phase III randomized TRIBE trial J Clin Oncol 30 2013 (suppl 34; abstract 336)
18. G. Masi, F. Loupakis, and L. Salvatore Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11 2010 845 852
19. C. Aggarwal, N.J. Meropol, and C.J. Punt Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer Ann Oncol 24 2013 420 428
20. S.J. Cohen, C.J.A. Punt, and N. Iannotti Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer J Clin Oncol 26 2008 3213 3221
21. S.J. Cohen, C.J.A. Punt, and N. Iannotti Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer Ann Oncol 20 2009 1223 1229
22. J. Tol, M. Koopman, and M.C. Miller Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents Ann Oncol 21 2010 1006 1012
23. J.S. de Bono, H.I. Scher, and R.B. Montgomery Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309
24. M. Cristofanilli, G.T. Budd, and M.J. Ellis Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 351 2004 781 791
25. M. Cristofanilli Circulating tumor cells, disease progression, and survival in metastatic breast cancer Semin Oncol 33 3 suppl 9 2006 S9 S14
26. J.-M. Hou, M.G. Krebs, and L. Lancashire Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer J Clin Oncol 30 2012 525 532
27. M.G. Krebs, R. Sloane, and L. Priest Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer J Clin Oncol 29 2011 1556 1563
28. L. Khoja, P. Lorigan, and C. Zhou Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma J Invest Dermatol 133 2013 1582 1590
29. J. Tol, M. Koopman, and A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
30. The Medicines for Human Use (Clinical Trials) Regulations 2004. Available at: http://www.legislation.gov.uk/uksi/2004/1031/contents/made. Accessed Jun 2014.
31. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
32. W.J. Allard, J. Matera, and M.C. Miller Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases Clin Cancer Res 10 2004 6897 6904
33. S. Riethdorf, H. Fritsche, and V. Muller Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system Clin Cancer Res 13 2007 920 928
34. J. Cummings, K. Morris, and C. Zhou Method validation of circulating tumour cell enumeration at low cell counts BMC Cancer 13 2013 415
35. J. Tabernero, F. Ciardiello, and F. Rivera Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study Ann Oncol 21 2010 1537 1545
36. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
37. G. Colucci, V. Gebbia, and G. Paoletti Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale J Clin Oncol 23 2005 4866 4875
38. L. Fornaro, S. Lonardi, and G. Masi FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO) Ann Oncol 24 2013 2062 2067
39. J.-Y. Douillard, P.M. Hoff, and J.R. Skillings Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 2002 3605 3616
40. J. Carmichael, T. Popiela, and D. Radstone Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 2002 3617 3627
41. J. Bennouna, M. Saunders, and J.-Y. Douillard The role of UFT in metastatic colorectal cancer Oncology 76 2009 301 310
42. E. Ozkumur, A.M. Shah, and J.C. Ciciliano Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells Sci Transl Med 5 2013 179ra47
43. M.G. Krebs, R.L. Metcalf, L. Carter, G. Brady, F.H. Blackhall, and C. Dive Molecular analysis of circulating tumour cells - biology and biomarkers Nat Rev Clin Oncol 11 2014 129 144
44. A.R. Thierry, F. Mouliere, and S. El Messaoudi Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Nat Med 20 2014 430 435
45. S. Misale, R. Yaeger, and S. Hobor Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
46. L.A. Diaz, R.T. Williams, and J. Wu The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 2012 537 540